Your browser doesn't support javascript.
loading
Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.
Iavarone, Claudia; Zervantonakis, Ioannis K; Selfors, Laura M; Palakurthi, Sangeetha; Liu, Joyce F; Drapkin, Ronny; Matulonis, Ursula A; Hallberg, Dorothy; Velculescu, Victor E; Leverson, Joel D; Sampath, Deepak; Mills, Gordon B; Brugge, Joan S.
Afiliación
  • Iavarone C; Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.
  • Zervantonakis IK; Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.
  • Selfors LM; Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.
  • Palakurthi S; Belfer Institute for Applied Cancer Res, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Drapkin R; Penn Ovarian Cancer Res Center, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
  • Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hallberg D; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Velculescu VE; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Leverson JD; Oncology Development, AbbVie, Inc., North Chicago, Illinois.
  • Sampath D; Translational Oncology, Genentech, South San Francisco, California.
  • Mills GB; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Brugge JS; Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts. joan_brugge@hms.harvard.edu.
Mol Cancer Ther ; 18(3): 642-655, 2019 03.
Article en En | MEDLINE | ID: mdl-30679390
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso / Proteínas Proto-Oncogénicas c-bcl-2 / Proteína bcl-X Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso / Proteínas Proto-Oncogénicas c-bcl-2 / Proteína bcl-X Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2019 Tipo del documento: Article